What's Happening?
Echosens, a global diagnostic company specializing in non-invasive medical devices, has appointed Romain Baujard as its new Group Chief Executive Officer, effective May 1, 2026. Baujard succeeds Dominique Legros, who is retiring after leading the company since
2019. Under Legros' leadership, Echosens expanded its global reach and increased the adoption of its technology. Baujard, who joined Echosens in 2015, has held various strategic roles, including Vice President of Pharma. He aims to integrate liver health as a vital sign in cardiometabolic care, leveraging Echosens' FibroScan technology and digital ecosystem.
Why It's Important?
The appointment of Romain Baujard marks a strategic shift for Echosens as it seeks to position liver health as a critical component of cardiometabolic care. This move reflects the growing recognition of liver health's role in managing metabolic diseases, which are on the rise globally. Baujard's leadership is expected to drive innovation and expand the company's market presence, particularly in early detection and risk management. The transition also highlights the importance of leadership continuity in maintaining and accelerating growth in the healthcare sector.
What's Next?
Under Baujard's leadership, Echosens plans to expand access to its technologies and enhance its digital and AI capabilities. The company aims to support clinicians beyond traditional specialties and integrate liver assessment into routine care. This strategic focus is expected to drive earlier detection and more effective management of liver-related conditions. Echosens' shareholders and leadership team express confidence in Baujard's ability to guide the company through its next growth phase, building on the strong foundation established by Dominique Legros.
